Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis

Eur Respir J. 2017 Apr 26;49(4):1700173. doi: 10.1183/13993003.00173-2017. Print 2017 Apr.

Authors

Lina Davies Forsman^{1

2}, Judith Bruchfeld^{1

2}, Jan-Willem C Alffenaar³

Affiliations

¹ Karolinska Institutet, Dept of Medicine, Unit of Infectious Disease, Stockholm, Sweden.
² Karolinska University Hospital, Dept of Infectious Disease, Stockholm, Sweden.
³ University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands [email protected].

PMID: 28446561
DOI: 10.1183/13993003.00173-2017

No abstract available

Publication types

Letter
Comment

MeSH terms

Antitubercular Agents
Drug Monitoring*
Drug Resistance / drug effects
Drug Resistance, Bacterial / drug effects
Fluoroquinolones*
Humans
Mycobacterium tuberculosis / drug effects
Tuberculosis
Tuberculosis, Multidrug-Resistant

Substances

Antitubercular Agents
Fluoroquinolones